

Reference:	FOI.16132.24
Subject:	Atopic Dermatitis
Date of Request:	4 December 2024

Requested:

- How many patients were treated in the last 4 months (August to November 2024) by the dermatology department with each of the following products:
 - Abrocitinib
 - Acitretin
 - Alitretinoin
 - Azathioprine
 - Baricitinib
 - Ciclosporin
 - Dupilumab
 - Lebrikizumab
 - Methotrexate
 - Mycophenolate mofetil
 - Pimecrolimus
 - Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
 - Tacrolimus ointment
 - Tralokinumab
 - Upadacitinib
 - Nemolizumab
- If possible, for the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:
 - 6 months to 5
 - Age 6-11
 - Age 12-17
 - Age 18 and above

Response:

- Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that were issued with the named biologic medications by the Dermatology department during the period 1 August to 30 November 2024.

Medication	Number
Abrocitinib	0
Acitretin	45
Alitretinoin	*
Azathioprine	9
Baricitinib	0
Ciclosporin	6
Dupilumab	95
Lebrikizumab	0
Methotrexate	96
Mycophenolate mofetil	6

Pimecrolimus	*
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	0
Tacrolimus ointment	*
Tralokinumab	7
Upadacitinib	7
Nemolizumab	0

2. The UHB provides within the table below, the age groups of patients that were issued with the named biologic medications listed in question (1) one during the period 1 August to 30 November 2024.

Age Group	Number
6 months - 5	*
Age 6 – 11	9
Age 12 – 17	23
Age 18 and above	243

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.